{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:05:34Z","timestamp":1781316334957,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.leukres.2023.107372","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:13:08Z","timestamp":1692465188000},"page":"107372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Canadian evidence-based guideline for treatment of relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1708","authenticated-orcid":false,"given":"Carolyn","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Eisinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5043-0557","authenticated-orcid":false,"given":"Andrew","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-3669","authenticated-orcid":false,"given":"Christine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107372_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107372_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107372_bib4","unstructured":"National Comprehensive Cancer Network (NCCN), NCCN Categories of Evidence and Consensus, (n.d.). \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-of-guidelines\u3009 (accessed March 22, 2023)."},{"key":"10.1016\/j.leukres.2023.107372_bib5","doi-asserted-by":"crossref","unstructured":"M. Hallek, B.D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, P. Hillmen, M. Keating, E. Montserrat, N. Chiorazzi, S. Stilgenbauer, K.R. Rai, J.C. Byrd, B. Eichhorst, T. Robak, J.F. Seymour, T.J. Kipps, Special Report iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, 2018.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"10.1016\/j.leukres.2023.107372_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2023.107372_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107016","article-title":"Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update","volume":"125","author":"Owen","year":"2023","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2023.107372_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107372_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107372_bib11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2023.107372_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3324\/haematol.2020.266486","article-title":"The impact of early discontinuation\/dose modification of venetoclax on outcomes in patients with relapsed\/refractory chronic lymphocytic the phase IIIleukemia: MURANO post-hoc study analyses from","volume":"107","author":"Mato","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107372_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/10428194.2023.2199340","article-title":"Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada","volume":"64","author":"Khelifi","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2023.107372_bib14","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.3747\/co.26.4957","article-title":"Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre","volume":"26","author":"Uminski","year":"2019","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib15","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic","author":"Ghia","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107372_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2023.107372_bib17","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107372_bib19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107372_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2944.2944","article-title":"Comparing Single-agent ibrutinib, bendamustine plus rituximab (BR) and Ibrutinib Plus BR in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an indirect comparison of the RESONATE and HELIOS trials","volume":"126","author":"Hillmen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib21","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107372_bib22","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2023.107372_bib23","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107372_bib25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107372_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107372_bib28","doi-asserted-by":"crossref","unstructured":"J.P. Sharman, S.E. Coutre, R.R. Furman, B.D. Cheson, J.M. Pagel, P. Hillmen, J.C. Barrientos, A.D. Zelenetz, T.J. Kipps, I.W. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A.R. Pettitt, S. Ma, E. Tausch, P. Cramer, J. Huang, S. Mitra, M. Hallek, S.M. O, S. Stilgenbauer, Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia, J Clin Oncol. 37 (2019) 1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.18.","DOI":"10.1200\/JCO.18.01460"},{"key":"10.1016\/j.leukres.2023.107372_bib29","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2023.107372_bib30","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2023.0190","article-title":"Clinical trials portfolio and regulatory history of idelalisib in indolent non-hodgkin lymphoma: a systematic review and meta-analysis","author":"Banerjee","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.leukres.2023.107372_bib32","unstructured":"Inc. Gilead Sciences, Gilead Statement on Zydelig\u00ae U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia, (2022). \u3008https:\/\/www.gilead.com\/news-and-press\/company-statements\/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia\u3009 (accessed July 27, 2023)."},{"key":"10.1016\/j.leukres.2023.107372_bib33","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib34","first-page":"8","article-title":"Umbralisib plus ublituximab is superior to obinutuzumab plus chlorambucil in patients with treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: Results from the phase 3 unity-cll study","volume":"19","author":"Barr","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib35","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3390\/curroncol30050339","article-title":"Impact of fixed-duration oral targeted therapies on the economic burden of chronic lymphocytic leukemia in Canada","volume":"30","author":"Lachaine","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107372_bib38","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib39","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107372_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107372_bib42","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2023.107372_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107372_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or Bcl-2 targeting","author":"Mhibik","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107372_bib46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib47","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib48","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107372_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107372_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113295","article-title":"Five-year follow-up of safety and efficacy of a phase III randomized trial of ofatumumab therapy versus physicians\u2019 choice in patients with bulky fludarabine refractory chronic lymphocytic leukemia","volume":"132","author":"Miklos","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107372_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/10428194.2013.809073","article-title":"Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia","volume":"55","author":"Robak","year":"2014","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:31Z","timestamp":1758935071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":51,"alternative-id":["S0145212623006379"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107372","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian evidence-based guideline for treatment of relapsed\/refractory chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107372"}}